Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Grazia Valsecchi

Showing results (271-280 of 326) with videos related to

Pageof 33
Sort By:
Blood|July 2, 2010
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 StudyGeorg Mann, Andishe Attarbaschi, Martin Schrappe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
European Geriatric Medicine|March 13, 2026
Association of pre- and postoperative delirium with functional status at discharge after hip fracture: findings from the Gruppo Italiano di Ortogeriatria (GIOG 2.0) studyMaria Cristina Ferrara, Francesca Remelli, Caterina Trevisan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 24, 2021
Machine learning in primary biliary cholangitis: A novel approach for risk stratificationAlessio Gerussi, Damiano Verda, Davide Paolo Bernasconi, et al.
Haematologica|May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2019
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyRob Pieters, Paola De Lorenzo, Philip Ancliffe, et al.
British Journal of Haematology|August 16, 2002
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP groupAnna Maria Testi, Ilaria Del Giudice, William Arcese, et al.
Aging Clinical and Experimental Research|February 7, 2020
Three-year National report from the Gruppo Italiano di Ortogeriatria (GIOG) in the management of hip-fractured patientsMaria Cristina Ferrara, Anita Andreano, Elena Tassistro, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Pageof 33

Showing results (271-280 of 326) with videos related to

Sort By:
Pageof 33
Blood|July 2, 2010
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 StudyGeorg Mann, Andishe Attarbaschi, Martin Schrappe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
European Geriatric Medicine|March 13, 2026
Association of pre- and postoperative delirium with functional status at discharge after hip fracture: findings from the Gruppo Italiano di Ortogeriatria (GIOG 2.0) studyMaria Cristina Ferrara, Francesca Remelli, Caterina Trevisan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 24, 2021
Machine learning in primary biliary cholangitis: A novel approach for risk stratificationAlessio Gerussi, Damiano Verda, Davide Paolo Bernasconi, et al.
Haematologica|May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2019
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyRob Pieters, Paola De Lorenzo, Philip Ancliffe, et al.
British Journal of Haematology|August 16, 2002
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP groupAnna Maria Testi, Ilaria Del Giudice, William Arcese, et al.
Aging Clinical and Experimental Research|February 7, 2020
Three-year National report from the Gruppo Italiano di Ortogeriatria (GIOG) in the management of hip-fractured patientsMaria Cristina Ferrara, Anita Andreano, Elena Tassistro, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Pageof 33